Antony Jackson Arumairaj

Dr. Antony Jackson Arumairaj

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2026 in Livers
Verified
Journal Article
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
DDDili Dhanani
Dili Dhanani
AVAnuradha Shunmugam Veluswamy
Anuradha Shunmugam Veluswamy
AKAbhishek kumar Mariswamy Mariswamy Arun Kumar
Abhishek kumar Mariswamy Mariswamy Arun Kumar
JMJose Andres Perez Moscoso
Jose Andres Perez Moscoso
PDPoojaben Dhorajiya
Poojaben Dhorajiya
Introduction: COVID-19, in addition to its direct detrimental respiratory infection, is associated with multiple systemic complications involving different organs, including the liver. COVID-19 has been associated with liver injury through multiple mechanisms, including direct viral effects on liver cells, immune-mediated injury, cytokine-driven inflammation, ischemic hepatitis, microvascular thrombosis, and sepsis-related multiorgan dysfunction. Acute liver failure (ALF) is the acute form of liver damage, which has a high mortality, and recovery is dependent on various factors. We studied the effect of COVID-19 on clinical outcomes such as mortality, length of stay, and need for non-invasive and invasive ventilation in patients with acute liver failure. Methods: We performed a retrospective cohort analysis using the Nationwide Inpatient Sample (NIS) database from 2020 to 2022. Adult patients admitted to the hospital with acute liver failure were divided into 2 groups based on their COVID-19 infection status. We analyzed differences in mortality, length of stay, need for non-invasive and invasive ventilation, acute kidney injury, need for renal replacement therapy, and total charges to evaluate the effects on outcomes, and the results were then adjusted for demographic and hospital factors. Results: Of 633,155 patients with acute liver failure, 66,785 had concurrent COVID-19 infection, while 566,370 did not. Patients with concurrent COVID-19 infection had significantly higher in-hospital mortality (63.9% vs. 36.0%) and greater utilization of noninvasive ventilation (14.9% vs. 6.4%), invasive mechanical ventilation (68.9% vs. 41.7%), higher incidence of acute kidney injury (81.4% vs. 70.3%) and higher need for renal replacement therapy (26.8% vs. 16.9%). They also experienced longer hospital stays (17.1 vs. 10.7 days) and higher total charges ($345,072 vs. $221,268). The findings were statistically significant after adjusting for demographics and clinical factors. Conclusions: Patients hospitalized with acute liver failure and concurrent COVID-19 infection experienced worse clinical outcomes, including higher in-hospital mortality, greater need for ventilatory support and renal replacement therapy, and higher hospital resource utilization. Notably, COVID-19 was independently associated with worse outcomes even among patients with fewer baseline comorbidities. These findings underscore the importance of early recognition of COVID-19 in patients presenting with acute liver failure, as well as prompt, multidisciplinary management to optimize clinical outcomes.

12 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
DDDili Dhanani
Dili Dhanani
AVAnuradha Shunmugam Veluswamy
Anuradha Shunmugam Veluswamy
AKAbhishek kumar Mariswamy Mariswamy Arun Kumar
Abhishek kumar Mariswamy Mariswamy Arun Kumar
JMJose Andres Perez Moscoso
Jose Andres Perez Moscoso
PDPoojaben Dhorajiya
Poojaben Dhorajiya
Background: COVID-19, in addition to its direct detrimental respiratory infection, is associated with multiple systemic complications involving different organs, including the liver. COVID-19 has been associated with liver injury through multiple mechanisms including direct viral effects on liver cells, immune mediated injury, cytokine-driven inflammation, ischemic hepatitis, microvascular thrombosis, and sepsis-related multiorgan dysfunction. Acute liver failure (ALF) is the acute form of liver damage, which has a high mortality, and recovery is dependent on various factors. We studied the effect of COVID-19 on clinical outcomes such as mortality, length of stay, and need for non-invasive and invasive ventilation in patients with acute liver failure. Methods: We performed a retrospective cohort analysis using the Nationwide Inpatient Sample (NIS) database from 2020 to 2022. Adult patients admitted to the hospital with acute liver failure were divided into 2 groups based on their COVID-19 infection status. We analyzed the difference in the mortality, length of stay and need for non-invasive or invasive ventilation using odds ratio, to evaluate effects on outcomes, and results were then adjusted to demographic and hospital factors. Results: Patients with acute liver failure with COVID-19 had significantly increased in-hospital mortality (63.7 vs 35.3%), increased use of noninvasive ventilation (15.0% vs 6.5%) and invasive mechanical ventilation (68.5% vs 40.9%), along with a longer hospital stay (17.1 vs 10.7 days). The findings were concurrent with statistical significance after adjusting for demographics and clinical factors. Conclusions: Patients with COVID-19 infection admitted to the hospital with acute liver failure have poor clinical out-comes, with higher in-hospital mortality, higher need for ventilatory support, and longer length of stay. COVID-19 independently is associated with worse outcomes, which was noted even in individuals with less baseline comorbidities. Early recognition of COVID-19 infection and acute hepatic failure and prompt management by the multidisciplinary team is essential for better clinical outcomes.

1 October 2026 in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
DDDili Dhanani
Dili Dhanani
AVAnuradha Shunmugam Veluswamy
Anuradha Shunmugam Veluswamy
FTFatema Tashrifwala
Fatema Tashrifwala
MKManik Kuriti
Manik Kuriti
DKDivya Korpu
Divya Korpu
COVID-19 has resulted in more than 100 million reported infections in the United States. Hypertension is a highly prevalent comorbidity among adults hospitalized with COVID-19 and is commonly associated with cardiovascular disease, chronic kidney disease, endothelial dysfunction, and systemic inflammation. Our study aimed to evaluate the impact of hypertension on outcomes among COVID-19 hospitalizations. We conducted a retrospective study using the National Inpatient Sample. We included 5.9 million adult hospitalizations with confirmed COVID-19 between 2020 and 2022, of which 3.7 million had concomitant HTN and 2.2 million did not. After multivariable adjustment, HTN was associated with higher odds of noninvasive ventilation (aOR 1.40, 95% CI 1.37–1.43), acute kidney injury (aOR 1.64, 95% CI 1.62–1.67), renal replacement therapy (aOR 4.17, 95% CI 4.02–4.34), atrial fibrillation (aOR 1.76, 95% CI 1.74–1.79), acute myocardial infarction (aOR 1.52, 95% CI 1.48–1.56), ischemic stroke (aOR 1.50, 95% CI 1.44–1.57), cardiac arrest (aOR 1.21, 95% CI 1.17–1.25), severe COVID-19 (aOR 1.78, 95% CI 1.75–1.80), and critical COVID-19 (aOR 1.65, 95% CI 1.63–1.67). HTN was also associated with a slightly longer adjusted length of stay and higher adjusted total charges. The hypertension group had higher crude in-hospital mortality (12.6% vs. 9.3%); however, after multivariable adjustment, hypertension was associated with lower odds of in-hospital mortality (aOR 0.92, 95% CI 0.90–0.93; p < 0.001). Overall, hypertension was associated with increased inpatient morbidity and a complicated hospital course among hospitalizations with COVID-19, despite lower adjusted odds of in-hospital mortality.

12 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
PDPoojaben Dhorajiya
Poojaben Dhorajiya
JMJayesh Mittal
Jayesh Mittal
MKManik Kuriti
Manik Kuriti
VVVimala Sravanthi Vajjala
Vimala Sravanthi Vajjala
DDDili Dhanani
Dili Dhanani
Diabetes mellitus is highly prevalent in the United States and increases the risk of severe illness in patients with COVID-19. We compared outcomes in hospitalized COVID-19 patients with and without diabetes using the National Inpatient Sample (2020-2022), adjusting for confounders via multivariable logistic regression. Among 5,934,565 hospitalizations for COVID-19, 2,155,978 (36.3%) had concomitant diabetes. The diabetes group had higher unadjusted in-hospital mortality (13.5% vs. 10.1%), but was not independently associated with mortality after adjustment (aOR 0.98; 95% CI 0.97-1.00). However, diabetes was independently associated with higher incidence of acute respiratory failure (46.1% vs 42.3%, aOR 1.29; 95% CI: 1.27-1.30), greater need for invasive mechanical ventilation (aOR 1.22; 95% CI 1.20-1.24) and non-invasive ventilation (aOR 1.27; 95% CI 1.25-1.29). These patients also had higher rates of ARDS, acute kidney injury, renal replacement therapy, sepsis, septic shock, and vasopressor use, along with longer length of hospital stay and higher total charges of hospitalization. Mortality among COVID-19 patients with diabetes declined through 2020-2022 (15.8% to 8.4%). Diabetes was not independently associated with in-hospital mortality but was associated with greater respiratory, renal, hemodynamic complications and hospital resource utilization. Early recognition and management of diabetes is warranted in patients with COVID-19.

20 September 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
PDPoojaben Dhorajiya
Poojaben Dhorajiya
JMJayesh Mittal
Jayesh Mittal
MKManik Kuriti
Manik Kuriti
VVVimala Sravanthi Vajjala
Vimala Sravanthi Vajjala
DDDili Dhanani
Dili Dhanani
Background: Diabetes mellitus (DM) is highly prevalent in the United States and increases the risk of severe illness in patients with COVID-19. We compared outcomes among adult COVID-19 hospitalizations with and without DM. Methods: We compared the National Inpatient Sample (2020–2022), using multivariate regression to adjust for potential confounders. Results: Among 5,934,565 hospitalizations for COVID-19, 2,155,978 (36.3%) had concomitant DM. The DM group had higher unadjusted in-hospital mortality (13.5% vs. 10.1%) and was associated with higher mortality after adjustment (aOR 1.17; 95% CI, 1.15–1.19; p < 0.001). DM was also independently associated with higher odds of acute respiratory failure (46.1% vs. 42.3%; aOR 1.12; 95% CI, 1.11–1.13; p < 0.001), greater use of invasive mechanical ventilation (aOR 1.35; 95% CI, 1.33–1.37; p < 0.001) and non-invasive ventilation (NIV; aOR 1.42; 95% CI, 1.40–1.45; p < 0.001). COVID-19 hospitalizations with DM also had higher rates of acute respiratory distress syndrome, acute kidney injury, renal replacement therapy, sepsis, septic shock, and vasopressor use, along with longer length of hospital stay and higher total hospitalization charges. In-hospital mortality among COVID-19 hospitalizations with DM was lower in 2022 than in 2020 and 2021. Conclusions: DM was associated with higher in-hospital mortality and greater respiratory, renal, and hemodynamic complications and hospital resource utilization.

21 February 2024 in Cureus
Verified
Journal Article
Open access
PDF file
Antony Jackson ArumairajAntony Jackson Arumairaj
Antony Jackson Arumairaj
IHImnett Habtes
Imnett Habtes
HPHansang Park
Hansang Park
JVJulio C. Valencia-Manrique
Julio C. Valencia-Manrique
JAJennifer Arzu
Jennifer Arzu
TNThomas Newman
Thomas Newman
Objective The objective of this study is to compare the outcomes of hospital mortality, the requirement of invasive ventilation, vasopressor requirement, duration of vasopressor requirement, and duration of intensive care unit (ICU) stay among the different causes of sepsis and to determine which cause of sepsis had the most severe outcomes. Methods A retrospective chart review was done in critically ill adult patients who were admitted with sepsis to the ICU from July 2017 until July 2019. Acute Physiology and Chronic Health Evaluation (APACHE) IV scores were calculated on patients admitted to ICU on day one of ICU admission. Each patient was then evaluated for outcomes of hospital mortality, need for invasive ventilation, requirement of vasopressors, duration of vasopressors, and duration of ICU stay. The outcomes were then compared between the different sources of sepsis to determine which source of sepsis had the highest severity. Results In total, 176 patients were included in the study. Ninety-three patients were admitted with respiratory sepsis, 26 patients were admitted with gastrointestinal sepsis, 31 patients were admitted with urosepsis, and 26 patients were admitted with other miscellaneous causes of sepsis. The hospital mortality was highest in the respiratory sepsis group at 32%, with a trend towards statistical significance with a P value of 0.057. ICU stay duration was highest in patients with respiratory sepsis at six days, with a statistically significant P value of < 0.001. The need for invasive ventilation was highest in patients with respiratory sepsis at 64%, with a statistically significant P value of < 0.001. The requirement of vasopressor support was highest in patients with respiratory sepsis at 47% and the duration of vasopressors was highest in both respiratory and gastrointestinal sepsis at three days, however, there was no statistical significance. Conclusion Among the different origins of sepsis, the patients with respiratory sepsis had the most severe outcomes, with the highest need for invasive ventilation and the highest ICU stay duration.